These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1322 related articles for article (PubMed ID: 11099321)

  • 1. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma.
    Carella AM; Cavaliere M; Lerma E; Ferrara R; Tedeschi L; Romanelli A; Vinci M; Pinotti G; Lambelet P; Loni C; Verdiani S; De Stefano F; Valbonesi M; Corsetti MT
    J Clin Oncol; 2000 Dec; 18(23):3918-24. PubMed ID: 11099321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engraftment of HLA-matched sibling hematopoietic stem cells after immunosuppressive conditioning regimen in patients with hematologic neoplasias.
    Carella AM; Lerma E; Dejana A; Corsetti MT; Celesti L; Bruni R; Benvenuto F; Figari O; Parodi C; Carlier P; Florio G; Lercari G; Valbonesi M; Casarino L; De Stefano F; Geniram A; Venturino M; Tedeschi L; Palmieri G; Piaggio G; Podestà M; Frassoni F; Van Lint MT; Marmont AM; Bacigalupo A
    Haematologica; 1998 Oct; 83(10):904-9. PubMed ID: 9830799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells.
    Nademanee A; Sniecinski I; Schmidt GM; Dagis AC; O'Donnell MR; Snyder DS; Parker PM; Stein AS; Smith EP; Molina A
    J Clin Oncol; 1994 Oct; 12(10):2176-86. PubMed ID: 7523609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease.
    Anderlini P; Giralt S; Andersson B; Ueno NT; Khouri I; Acholonu S; Cohen A; Körbling MJ; Manning J; Romaguera J; Sarris A; Rodriguez ; Hagemeister F; Mclaughlin P; Cabanillas F; Champlin RE
    Bone Marrow Transplant; 2000 Sep; 26(6):615-20. PubMed ID: 11041566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma.
    Aurlien E; Holte H; Pharo A; Kvaløy S; Jakobsen E; Smeland EB; Kvalheim G
    Bone Marrow Transplant; 1998 May; 21(9):873-8. PubMed ID: 9613778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation.
    Porter DL; Luger SM; Duffy KM; Stadtmauer EA; Laport G; Schuster SJ; Orloff G; Tsai D; McDaid K; Kathakali A; Leonard DG; Antin JH
    Biol Blood Marrow Transplant; 2001; 7(4):230-8. PubMed ID: 11349810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Less intense conditioning with fludarabine, cyclophosphamide, idarubicin and etoposide (FCIE) followed by allogeneic unselected peripheral blood stem cell transplantation in elderly patients with leukemia.
    Schlenk RF; Hartmann F; Hensel M; Jung W; Weber-Nordt R; Gabler A; Haas R; Ho AD; Trümper L; Döhner H
    Leukemia; 2002 Apr; 16(4):581-6. PubMed ID: 11960336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma.
    Klumpp TR; Mangan KF; Glenn LD; Malaspina DR; Cropper T; Mullaney M; Macdonald JS
    Bone Marrow Transplant; 1993 Oct; 12(4):337-45. PubMed ID: 7506091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.
    Nagler A; Slavin S; Varadi G; Naparstek E; Samuel S; Or R
    Bone Marrow Transplant; 2000 May; 25(10):1021-8. PubMed ID: 10828860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic stem cell transplantation with BEAM and alemtuzumab conditioning immediately after remission induction has curative potential in advanced T-cell non-Hodgkin's lymphoma.
    Czajczynska A; Günther A; Repp R; Humpe A; Schub N; Raff T; Nickelsen M; Schrauder A; Schrappe M; Kneba M; Gramatzki M
    Biol Blood Marrow Transplant; 2013 Nov; 19(11):1632-7. PubMed ID: 23850653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid achievement of complete donor chimerism and low regimen-related toxicity after reduced conditioning with fludarabine, carmustine, melphalan and allogeneic transplantation.
    Wäsch R; Reisser S; Hahn J; Bertz H; Engelhardt M; Kunzmann R; Veelken H; Holler E; Finke J
    Bone Marrow Transplant; 2000 Aug; 26(3):243-50. PubMed ID: 10967561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation.
    Marks DI; Lush R; Cavenagh J; Milligan DW; Schey S; Parker A; Clark FJ; Hunt L; Yin J; Fuller S; Vandenberghe E; Marsh J; Littlewood T; Smith GM; Culligan D; Hunter A; Chopra R; Davies A; Towlson K; Williams CD
    Blood; 2002 Nov; 100(9):3108-14. PubMed ID: 12384406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
    Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
    Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
    Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
    Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peripheral blood progenitor cell mobilization with Dexa-Beam/G-CSF, ether lipid purging, and autologous transplantation after high-dose CBV treatment: a safe and effective regimen in patients with poor risk malignant lymphomas.
    Knauf WU; Koenigsmann MP; Notter M; Hoppe B; Reufi B; Oberberg D; Thiel E; Berdel WE
    Leuk Lymphoma; 1996 Oct; 23(3-4):305-11. PubMed ID: 9031111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose chemotherapy with BUCY or BEAC and unpurged peripheral blood stem cell infusion in patients with low-grade non-Hodgkin's lymphoma.
    Weaver CH; Schwartzberg L; Rhinehart S; West J; Zhen B; West WH; Buckner CD
    Bone Marrow Transplant; 1998 Feb; 21(4):383-9. PubMed ID: 9509973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BEAM allogeneic transplantation for patients with Hodgkin's disease who relapse after autologous transplantation is safe and effective.
    Cooney JP; Stiff PJ; Toor AA; Parthasarathy M
    Biol Blood Marrow Transplant; 2003 Mar; 9(3):177-82. PubMed ID: 12652468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimal residual disease.
    Vose JM; Sharp G; Chan WC; Nichols C; Loh K; Inwards D; Rifkin R; Bierman PJ; Lynch JC; Weisenburger DD; Kessinger A; Armitage JO
    J Clin Oncol; 2002 May; 20(9):2344-52. PubMed ID: 11981006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toxicity of high-dose sequential chemotherapy and purged autologous hematopoietic cell transplantation precludes its use in refractory/recurrent non-Hodgkin's lymphoma.
    Johnston LJ; Stockerl-Goldstein KE; Hu WW; Negrin RS; Hoppe RT; Blume KG; Horning SJ
    Biol Blood Marrow Transplant; 2000; 6(5A):555-62. PubMed ID: 11071261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicity.
    Cull GM; Haynes AP; Byrne JL; Carter GI; Miflin G; Rebello P; Hale G; Waldmann H; Russell NH
    Br J Haematol; 2000 Mar; 108(4):754-60. PubMed ID: 10792280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 67.